Does Amerigroup Cover Victoza?

How Amerigroup Formularies Work for Prescription Drugs

Amerigroup uses a tiered formulary system called a Preferred Drug List (PDL) that groups medications by cost and clinical preference, with each tier carrying different cost-sharing amounts. Because Amerigroup operates as a Medicaid managed care organization across more than 20 states (and also offers Medicare Advantage and Marketplace plans), the specific formulary varies depending on your state and plan type.

Medicaid formularies follow each state's preferred drug list. The Centers for Medicare and Medicaid Services (CMS) requires Medicaid plans to cover all FDA-approved drugs from participating manufacturers under the Medicaid Drug Rebate Program, though states can still impose prior authorization and preferred-status restrictions [1]. For Amerigroup Medicaid members, this means Victoza is technically accessible in every state, but the path to getting it approved involves clinical criteria your prescriber must document.

Medicare Advantage formularies follow CMS Part D rules instead. GLP-1 receptor agonists for diabetes must appear on Part D formularies per CMS guidelines, but plans have discretion over which tier a drug occupies [2]. Amerigroup's Medicare Advantage plans (branded as Wellpoint Medicare in some markets following the Elevance Health rebrand) generally place Victoza on Tier 3 or Tier 4. That tier placement directly affects your copay.

Victoza's Typical Tier Placement on Amerigroup Plans

Victoza sits on Tier 3 (preferred brand) in some Amerigroup state Medicaid formularies and on Tier 4 (non-preferred brand) in others. The distinction matters because it determines both your out-of-pocket cost and whether you need to try a cheaper drug first.

In states where Amerigroup lists a competing GLP-1 receptor agonist as the preferred agent (often Trulicity or Ozempic), Victoza drops to non-preferred status. A 2023 analysis published in Diabetes Care found that formulary restriction of GLP-1 receptor agonists increased treatment discontinuation rates by 32% compared with unrestricted access (Diabetes Care, 2023) [3]. That discontinuation risk is worth discussing with your prescriber if your Amerigroup plan lists Victoza as non-preferred.

For Medicaid specifically, federal rules cap copays. Most Amerigroup Medicaid members pay between $0 and $3.70 per prescription regardless of tier. Medicare Advantage members face a wider range. Tier 3 copays on Amerigroup Medicare Advantage plans typically run $35 to $47 for a 30-day supply, while Tier 4 copays can reach $75 to $95. Your plan's Evidence of Coverage document lists the exact amount.

Prior Authorization Requirements for Victoza on Amerigroup

Nearly every Amerigroup plan requires prior authorization (PA) before covering Victoza. Your prescriber's office submits the PA request, and Amerigroup's pharmacy team reviews it against a set of clinical criteria.

The standard PA criteria across most Amerigroup state plans include a confirmed diagnosis of type 2 diabetes with an HbA1c of 7.0% or higher despite oral therapy, documented trial and failure (or intolerance) of metformin for at least 90 days, age 18 or older (some state plans allow coverage starting at age 10 per the FDA-approved pediatric indication), and prescribing by or in consultation with an endocrinologist or primary care physician managing the diabetes.

Some state Amerigroup plans add a second step therapy requirement. In Texas and Georgia, for example, Amerigroup's Medicaid PDL has historically required failure on both metformin and a sulfonylurea before approving any GLP-1 receptor agonist [4]. The American Diabetes Association's Standards of Care 2024 recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease, regardless of HbA1c, which gives your prescriber a strong guideline-based argument for the PA request [5].

PA decisions typically take 24 to 72 hours. If denied, you have the right to appeal. Amerigroup must process standard appeals within 30 days for Medicaid and 7 days for Medicare Advantage Part D, per CMS regulations.

Step Therapy: What You Need to Try Before Victoza

Step therapy is the most common barrier Amerigroup members face when trying to get Victoza covered. The logic behind it is straightforward: insurers want documentation that less expensive treatments were insufficient before approving a branded injectable that costs over $1,100 per month at retail.

The typical step therapy sequence on Amerigroup plans starts with metformin (first-line, per ADA guidelines). Metformin costs roughly $4 to $15 per month as a generic, and the ADA Standards of Care endorse it as initial pharmacotherapy for most adults with type 2 diabetes [5]. If metformin alone does not achieve the target HbA1c after three to six months, many Amerigroup plans then require trial of a sulfonylurea (glipizide or glimepiride) or an SGLT2 inhibitor before approving a GLP-1 receptor agonist.

There are clinical exceptions. Patients with established cardiovascular disease or chronic kidney disease may qualify for GLP-1 receptor agonist coverage without completing full step therapy. The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced the composite cardiovascular outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% compared with placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.87, 95% CI 0.78-0.97, P=0.01) (NEJM, 2016) [6]. Your prescriber can cite this trial data in the PA request to argue for cardiovascular-indicated use without completing step therapy.

A second exception applies to patients who cannot tolerate metformin due to gastrointestinal side effects or who have an estimated GFR below 30 mL/min/1.73 m², where metformin is contraindicated per FDA labeling [7]. Document the intolerance or contraindication clearly, because Amerigroup's pharmacy benefit managers review these claims carefully.

What Victoza Costs with Amerigroup vs. Without Insurance

The cost difference between covered and uncovered Victoza is significant. Understanding the numbers helps you plan for out-of-pocket expenses regardless of your coverage status.

Without any insurance, Victoza's wholesale acquisition cost (WAC) is approximately $1,175 for a 30-day supply (two 6 mg/mL pens, each containing 18 mg of liraglutide). Retail pharmacy prices vary. GoodRx and similar discount platforms show cash prices ranging from $1,050 to $1,400 depending on the pharmacy. Novo Nordisk, the manufacturer, offers a Victoza Savings Card that can reduce the monthly cost to $25 for commercially insured patients, though this card typically does not apply to Medicaid or Medicare beneficiaries due to federal anti-kickback statute restrictions [8].

With Amerigroup Medicaid, your cost drops dramatically. Federal Medicaid copay caps set maximum cost-sharing at $4 for preferred drugs and $8 for non-preferred drugs, and many states set even lower thresholds [1]. Most Amerigroup Medicaid members pay $0 to $3.70 per fill for Victoza once prior authorization is approved.

With Amerigroup Medicare Advantage, costs depend on your plan's specific tier structure and where you fall in the Part D coverage phases. During the initial coverage phase, expect $35 to $95 per month. After reaching the coverage gap (the "donut hole" threshold was $5,030 in total drug costs for 2024), manufacturer discounts under the Part D Coverage Gap Discount Program reduce your brand-name drug cost-sharing, and the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits total Part D spending for Medicare beneficiaries [9].

How to Check Your Specific Amerigroup Formulary

Because Amerigroup formularies differ by state and plan type, checking your own plan's drug list is the most reliable way to confirm Victoza coverage. There are several practical ways to do this.

Call the Amerigroup member services number on the back of your insurance card. Ask specifically whether liraglutide 1.8 mg (Victoza) is on your plan's formulary, which tier it occupies, and what prior authorization criteria apply. Request the information in writing or ask for a reference number for the call.

Visit the Amerigroup website for your state. Each state's Amerigroup portal hosts a searchable formulary. Select your specific plan, then search for "liraglutide" or "Victoza." The result will show the tier, PA requirements, quantity limits, and any step therapy prerequisites.

Ask your prescriber's office to run a real-time benefit check. Most electronic health record systems integrate with pharmacy benefit verification tools that show your plan's coverage for a specific medication at the point of prescribing. This check reveals the estimated copay, PA requirements, and any preferred alternatives, all before the prescription reaches the pharmacy.

Review your Evidence of Coverage (EOC) document. For Medicare Advantage members, the EOC is the binding legal document that details your drug benefit. Amerigroup mails it annually and posts it online. The formulary appendix lists every covered drug, its tier, and any coverage rules.

Alternatives if Amerigroup Does Not Cover Victoza or Requires a Switch

If your Amerigroup plan denies Victoza coverage or places it on a non-preferred tier with high cost-sharing, several therapeutic alternatives within the GLP-1 receptor agonist class may be available at lower cost on your formulary.

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly injection) is preferred on many Amerigroup formularies. The SUSTAIN-7 trial (N=1,201) directly compared semaglutide with dulaglutide and found semaglutide 1.0 mg produced significantly greater HbA1c reduction (-1.8% vs. -1.4%) and weight loss (-6.5 kg vs. -3.0 kg) at 40 weeks (The Lancet Diabetes & Endocrinology, 2018) [10].

Trulicity (dulaglutide 0.75 mg or 1.5 mg weekly injection) holds preferred status on several Amerigroup state formularies. It requires only once-weekly dosing compared with Victoza's daily injection.

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that showed superior glycemic control in the SURPASS trial program. The SURPASS-2 trial (N=1,879) demonstrated HbA1c reductions of up to -2.37% with tirzepatide 15 mg vs. -1.86% with semaglutide 1 mg at 40 weeks (NEJM, 2021) [11]. Amerigroup's coverage of tirzepatide varies by state and is expanding.

Rybelsus (oral semaglutide 7 mg or 14 mg) offers a non-injectable option within the GLP-1 class. Some patients prefer it to avoid injections entirely. The PIONEER-4 trial (N=711) showed oral semaglutide 14 mg was non-inferior to liraglutide 1.8 mg (Victoza) for HbA1c reduction at 26 weeks and produced greater weight loss (-4.4 kg vs. -3.1 kg) (The Lancet, 2019) [12].

If your prescriber believes Victoza is specifically the right medication for your clinical situation (for example, if you participated in the LEADER trial population with established cardiovascular disease), a peer-to-peer review between your prescriber and Amerigroup's medical director can often resolve a coverage denial.

The Appeal Process When Amerigroup Denies Victoza

Denials happen. Knowing the appeal timeline and what documentation strengthens your case increases the likelihood of a reversal.

For Medicaid members, Amerigroup must issue a written denial notice (called an Adverse Benefit Determination) explaining the reason. You or your prescriber can file an internal appeal within 60 days of the denial in most states. Amerigroup must decide within 30 days for standard appeals or 72 hours for expedited appeals when delay could seriously jeopardize your health [1]. If the internal appeal fails, you can request a State Fair Hearing, an independent review by your state Medicaid agency.

For Medicare Advantage members, the Part D appeals process has five levels. The first is redetermination by Amerigroup (decided within 7 days for standard, 72 hours for expedited). If denied again, the second level is review by an Independent Review Entity, which is decided within 7 days. Beyond that, cases can escalate to an Administrative Law Judge, the Medicare Appeals Council, and federal court [2].

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Barriers to accessing GLP-1 receptor agonists, including step therapy and prior authorization, can delay evidence-based treatment for patients with type 2 diabetes who have clear cardiovascular and renal benefit indications" (ADA, Standards of Care 2024) [5].

Documentation that strengthens an appeal includes a letter of medical necessity from your prescriber citing specific clinical trial data (LEADER for cardiovascular benefit, for example), laboratory records showing HbA1c trends before and after oral agent therapy, pharmacy records proving the required step therapy drugs were tried and failed, and any specialist consultation notes supporting the GLP-1 receptor agonist indication.

The Endocrine Society's 2022 Clinical Practice Guideline on Pharmacological Management of Type 2 Diabetes recommends GLP-1 receptor agonists as preferred second-line agents over sulfonylureas and DPP-4 inhibitors for most patients, providing additional guideline-level support for appeal letters [13].

Victoza for Weight Loss: A Different Coverage Question

Victoza is FDA-approved only for type 2 diabetes at the 1.8 mg dose. Saxenda (liraglutide 3.0 mg) is the obesity-specific formulation of the same drug. Amerigroup's coverage rules differ significantly between the two.

Most Amerigroup Medicaid plans do not cover anti-obesity medications, including Saxenda. Medicaid has historically excluded weight loss drugs from mandatory coverage under federal law, though some states have begun voluntarily covering them [14]. If you are seeking liraglutide specifically for weight management without a type 2 diabetes diagnosis, Amerigroup Medicaid will almost certainly deny the claim.

Amerigroup Medicare Advantage plans may cover Saxenda if the plan includes supplemental drug benefits for weight management, but this is uncommon. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times to mandate Medicare Part D coverage of anti-obesity medications, but as of mid-2026, it has not been enacted.

If your prescriber documents that you have both type 2 diabetes and obesity (BMI 30 or higher), Victoza at 1.8 mg prescribed for the diabetes indication is the covered path. The SCALE Diabetes trial (N=846) showed liraglutide 3.0 mg produced 6.0% mean weight loss at 56 weeks in patients with type 2 diabetes and BMI of 27 or higher (JAMA, 2015), though the 1.8 mg diabetes dose also produced clinically meaningful weight reduction of 4.7% in that same trial [15].

Tips for Getting Victoza Approved Through Amerigroup Faster

Start metformin early if your prescriber anticipates you will need a GLP-1 receptor agonist. Documenting a 90-day metformin trial satisfies most Amerigroup step therapy requirements. If metformin causes intolerable gastrointestinal symptoms, have your prescriber document the specific adverse effects and the date treatment was discontinued.

Ask your prescriber to submit the prior authorization proactively, before sending the prescription to the pharmacy. Reactive PAs (triggered by a pharmacy rejection) add days to the process. Proactive PAs can be approved before you ever arrive at the pharmacy counter.

Use the correct diagnosis codes. ICD-10 code E11 (type 2 diabetes mellitus) with appropriate subcodes for complications (E11.65 for hyperglycemia, E11.9 for unspecified) must appear on the PA request. If cardiovascular disease is present, include I25.10 (atherosclerotic heart disease) or the relevant vascular code to support guideline-based bypassing of step therapy per ADA recommendations [5].

Keep copies of all PA submissions, denial letters, and appeal documents. If you switch Amerigroup plans during open enrollment or move to a different state, previously approved PAs may not transfer. Having your documentation organized means your new plan's PA can be processed faster with the same supporting evidence.